A better fit? Biotech versus Big Pharma in orphan/rare disease drug research-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A better fit? Biotech versus Big Pharma in orphan/rare disease drug research

Published:2014-03-22 Issue:4 Volume:2 Page:317-319
ISSN:2167-8707
Container-title:Expert Opinion on Orphan Drugs
language:en
Short-container-title:Expert Opinion on Orphan Drugs

Author:

O’Neil Deborah A

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Link

http://www.tandfonline.com/doi/pdf/10.1517/21678707.2014.900433

Reference1 articles.

1. Orphan products: an emerging trend in drug approvals

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences;Orphanet Journal of Rare Diseases;2023-09-12

2. CDMOs Play a Critical Role in the Biopharmaceutical Ecosystem;Frontiers in Bioengineering and Biotechnology;2022-03-21

3. Utilization of biotechnological drugs in rare diseases requiring the use of off-label drugs in children in Turkey;TURKISH JOURNAL OF MEDICAL SCIENCES;2021-08-30

4. The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study;Orphanet Journal of Rare Diseases;2019-11-04

5. Improving market access to rare disease therapies: A worldwide perspective with recommendations to the industry;Medicine Access @ Point of Care;2018-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP